NCT06612775View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions

Focal Epilepsy

Interventions

DRUG

Test drug CB03-154 5mg group

CB03-154 tablet (5mg/tablet) once daily.

DRUG

Test drug CB03-154 10mg group

Two CB03-154 tablets (5mg/tablet) once daily.

DRUG

Test drug CB03-154 20mg group

Four CB03-154 tablets (5mg/tablet) once daily.

DRUG

Placebo group

Four Placebo tablets once daily.

All Listed Sponsors

lead

Shanghai Zhimeng Biopharma, Inc.

INDUSTRY

NCT06612775 - A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy | Biotech Hunter | Biotech Hunter